[From Abstract:] Plasma kallikrein (pKal) is a serine protease responsible for cleaving high-molecular-weight kininogen to produce the pro-inflammatory peptide, bradykinin. Unregulated pKal activity can lead to hereditary angioedema (HAE) following excess bradykinin release. HAE attacks can lead to a compromised airway that can be life threatening. As there are limited agents for prophylaxis of HAE attacks, there is a high unmet need for a therapeutic agent for regulating pKal with a high degree of specificity… [continue reading]
Full Citation: Partridge J, Choy R, Silva-Garcia A, et al. Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition. Journal of Structural Biology. In Press, Accepted Manuscript. Available Online 12 March 2019.